Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676140 | 0.85 | MGLL (0.37) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL354292 | 0.84 | CYP2A6 (0.48) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL2387149 | 0.83 | MGLL (0.47) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL16009726 | 0.83 | MGLL (0.52) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL28019294 | 0.81 | MGLL (0.50) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL12778749 | 0.79 | MGLL (0.44) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL2387733 | 0.79 | CYP2A6 (0.44) | MGLLCYP2A6ADRB2HDAC3HDAC4 | |
| SCHEMBL2388308 | 0.79 | MGLL (0.44) | MGLLCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL17676139 | 0.79 | PIK3CA (0.42) | HDAC1APPHSD17B1HSD17B2 | |
| SCHEMBL2708073 | 0.78 | STS (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | OMNISINO HEALTH (TIANJIN) MEDICAL TECHNOLOGY CO. LTD (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | OMNISINO HEALTH (TIANJIN) MEDICAL TECHNOLOGY CO. LTD (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| EP-1715025-A1 | METHOD OF DESULFURIZING HYDROCARBON OIL | JAPAN ENERGY CORPORATION (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024500-B2 | Five-membered ring-substituted pyridazinol compounds and derivatives, preparation methods, herbicidal compositions and applications thereof | DDT, CYP3A5, CYP4B1 | MGLL 402/4885CYP2A6 153/4885ADRB2 1033/4885 |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | MGLL 4563/4885CYP2A6 798/4885ADRB2 141/4885 |
| US-20230372375-A1 | SGLT-2 INHIBITOR SARCOSINE CO-CRYSTAL, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC5A2, SLC5A1, SLC2A2 | MGLL 2376/4885CYP2A6 1652/4885ADRB2 1121/4885 |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | MGLL 3315/4885CYP2A6 2231/4885ADRB2 286/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | MGLL 4033/4885CYP2A6 805/4885ADRB2 48/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | MGLL 2220/4885CYP2A6 1948/4885ADRB2 280/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | MGLL 4582/4885CYP2A6 481/4885ADRB2 3955/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | MGLL 400/4885CYP2A6 4174/4885ADRB2 99/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | MGLL 3525/4885CYP2A6 668/4885ADRB2 2137/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | MGLL 4412/4885CYP2A6 3572/4885ADRB2 1069/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MGLL 906/4885CYP2A6 4656/4885ADRB2 3740/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | MGLL 3431/4885CYP2A6 947/4885ADRB2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.